1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shandong Wohua Pharmaceutical Co., Ltd.

Shandong Wohua Pharmaceutical Co., Ltd.

002107.SZ
Shandong Wohua Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
6.28
CNY
+0.17
- -
3.62BMarket Cap
Shandong Wohua Pharmaceutical Co., Ltd.
002107.SZ
(Shenzhen Stock Exchange)

Recent

price

6.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.16
0.28
0.36
0.41
0.76
0.82
1.01
1.27
1.38
1.53
1.74
1.62
1.8
1.55
1.26
1.45
1.39
Revenue per Share
-0.17
0.01
0.01
0.02
0.08
0.12
0.09
0.1
0.08
0.17
0.31
0.28
0.19
0.1
0.06
0.17
0.12
Basic EPS, GAAP
-0.06
-0.07
0.01
- -
0.05
0.22
0.08
0.19
0.08
- -
0.25
0.31
0.32
0.22
0.14
0.23
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.02
0.06
0.06
- -
- -
0.03
0.08
0.27
0.27
- -
0.24
0.12
- -
Dividend per Share
0.41
0.44
0.41
0.4
0.5
0.83
0.86
0.94
1.03
1.14
1.32
1.3
1.25
1.29
1.07
1.18
1.22
Book Value per Share
0.99
1.09
0.9
0.88
1.19
0.77
0.85
1.02
1.12
1.24
1.41
1.44
1.28
1.3
1.08
1.16
1.21
Tangible Book Value per Share
574
523
587
623
578
571
558
570
562
564
577
584
565
588
607
563
571
Basic Weighted Avg Shares
91
149
210
256
438
469
563
727
774
860
1,006
943
1,015
910
764
817
794
Sales/Revenue/Turnover
-39.03
2.58
3.16
2.52
9.72
17.32
12.87
16.76
7.09
13.16
21.53
21.95
11.08
5.77
5.62
11.84
9.14
Operating Margin (%)
8
10
12
15
22
22
19
20
19
19
28
33
35
33
32
32
- -
Depreciation Expense
-98
7
8
11
43
71
49
57
46
96
179
163
107
59
36
96
70
Net Income, GAAP
- -
0.12
0.06
0.03
3.25
4.16
12.37
11.89
8.27
13.89
15.48
15.07
18.87
14.66
20.84
13.27
13.75
Effective Tax Rate (%)
-107.58
4.99
3.98
4.16
9.9
15.22
8.67
7.85
5.89
11.14
17.78
17.33
10.58
6.46
4.77
11.72
8.82
Profit Margin (%)
378
372
347
365
474
264
285
349
349
406
371
417
316
385
301
326
352
Working Capital
10
- -
- -
- -
- -
30
30
- -
- -
- -
- -
- -
- -
- -
1
- -
1
LT Debt
591
586
594
605
801
547
573
656
696
775
918
929
790
833
723
721
760
Total Equity
- -
0.72
1.17
1.07
5.81
11.16
10.63
16.48
7.22
13.16
19.25
17.01
10.37
5.4
4.31
11.46
8.49
Return on Invested Capital (%)
- -
3.34
1.93
3.27
11.79
13.16
6.19
6.54
7.9
13.23
19.36
17.53
15.41
9.2
5.32
15.34
10.91
Return on Capital (%)
-34.53
3.2
3.56
4.36
16.05
18.71
10.24
11.2
8.2
15.69
25.4
21.43
14.63
8.01
5.16
14.58
10.58
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
577
577
577
Market Capitalization
2,310
2,532
3,269

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
543
586
615
Cash, Cash Equivalents & STI
345
404
431
Accounts Receivable, Net
63
66
68
Inventories
107
99
101
Total Current Liabilities
242
259
262
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.33%
-4.36%
-0.28%
Free Cash Flow
-2,501.04%
2.3%
45.59%
Net Income, GAAP
19.85%
7.33%
162.93%
Sales/Revenue/Turnover
6.57%
-3.62%
6.96%
Total Cash Common Dividend
- -
- -
-52%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
215
180
182
187
764
2025
218
208
192
- -
817
2026
219
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.06
2025
0.04
- -
- -
- -
0.17
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.24
2025
- -
- -
- -
- -
0.12
2026
0.14
- -
- -
- -
- -
Similar Companies
Valiant Laboratories Limited (VALIANTLAB.NS)
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
Lumiera Health Inc. (NHP.V)
Vita Life Sciences Limited (VLS.AX)
Sumitomo Pharma Co., Ltd. (4506.T)
Planet 13 Holdings Inc. (PLTH.CN)
Business
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) researches, develops, manufactures and markets proprietary Chinese medicines principally targeting cardiovascular, cerebrovascular, nervous system, orthopedic, respiratory and pediatric diseases; its core products include Xinkeshu tablets (Wohua Xinkeshu tablets) for cardiovascular conditions, Hedan tablets and capsules (Hodan) for cerebrovascular ailments, Gusu Kang capsules and granules (osteoporosis products), Naoxueshu oral solutions, Brain Hemorrhage oral solution (Nao Xueshu), Amber Stone Granules, Yuandu Hanbi Liquid, and Orange Red Pear Paste, offered in forms such as tablets, hard capsules, granules, pills, oral liquids, mixtures, powders and ointments. Founded in 2003 with roots tracing back over 200 years to Wanhetang Pharmaceutical in China's Qing Dynasty, the company is headquartered in Weifang, Shandong province, China, and operates production facilities including subsidiaries Jiangxi Wohua Jishun Pharmaceutical Co., Ltd. and Liaoning Wohua Kangchen Pharmaceutical Co., Ltd., acquired in 2015 to expand its resource-sharing network. Recent developments encompass the launch of Biliqi lysine calcium hydrogen phosphate granules at Wohua Kangchen leveraging surplus capacity, a strategic partnership with 1YaoWang (1drug network) to build a cardiovascular "medicine + service" ecosystem, publication of expert consensus on Xinkeshu tablets for coronary heart disease with anxiety/depression, award of Shandong Science and Technology Progress Second Prize for Xinkeshu research, and initiation of a registration study for Brain Hemorrhage oral solution.